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Aspirin (ASA) plays a key role in protecting high risk cardiovascular patients from ischaemic
events. The modiﬁcations underlying its effects are the results of the trans-acetylation that
occurs between ASA and the amino groups made up of lysine and N-terminal residues. ASA’s
effects have also been demonstrated on several plasma proteins, including human serum
albumin (HSA). However, its beneﬁcial effects seem to be lower in diabetic patients, sug-
gesting that protein glycation may impair ASA’s acetylation process. Using immunoblotting
and mass spectrometry, this study characterized the degree of HSA acetylation mediated by
ASA  in vitro, as well as the impact of high glucose concentrations. Glycation’s inﬂuence on
HSA acetylation might impair the latter’s biological functions, leading to a potential failureAcetylation
Glycation
Human serum albumin
Lysine
Mass spectrometry
of  ASA to prevent cardiovascular complications in diabetes.
©  2014 The Authors. Published by Elsevier B.V. on behalf of European Proteomics
Association (EuPA). Open access under CC BY-NC-SA license.1.  Introduction
Since its serendipitous discovery and thanks to mid-20th
century improvements, aspirin, also known as acetylsalicylic
acid (ASA), has become a landmark drug in the history of
medicine. ASA is the world’s most well-known non-steroidal
anti-inﬂammatory drug; this is due to its pleiotropic effects,
either in the ordinary treatment of pain, fever and inﬂam-
mation, or in clinical practice [1,2]. Indeed, it is widely used
Abbreviations: ASA, acetyl salicylic acid; HCD, high energy collisional 
∗ Corresponding author at: Translational Biomarker Group, Departmen
Servet  1, 1211 Geneva 4, Switzerland. Tel.: +41 022 3795486; fax: +41 022
E-mail address: Jean-Charles.Sanchez@unige.ch (J.-C. Sanchez).
http://dx.doi.org/10.1016/j.euprot.2014.02.001
2212-9685 © 2014 The Authors. Published by Elsevier B.V. on behalf ofas a preventive agent in atherothrombotic diseases, because
of its inhibition of the COX-1 platelet enzyme [3]. It also
enhances the resolution of inﬂammatory states by increas-
ing the activity of the COX-2 vascular enzyme [4], and thus
prevents the risk of cardiovascular ischaemic events [5,6].
ASA plays a relevant role in lowering insulin resistance,
by reducing levels of pro-inﬂammatory cytokines [7], anddissociation; HSA, human serum albumin; MS, mass spectrometry.
t of Human Protein Sciences, University of Geneva, Rue Michel
 3795505.
furthermore it exerts its therapeutic action through the trans-
fer of its acetyl moiety to the primary amino groups of
proteins located at lysine and N-terminal residues. Under
 European Proteomics Association (EuPA). Open access under CC BY-NC-SA license.
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hysiological conditions (37 ◦C, pH 7.4) this reaction is fast
nd follows a ﬁrst order kinetic dependent only on the con-
entration of ASA. After usual therapeutic doses, normal ASA
lasma levels range from 0.7 to 2.2 mM,  however toxicity can
ccur when serum concentrations exceed 2.9–3.6 mM and can
ecome fatal beyond 5.4 mM [8]. Several studies have shown
he effect of ASA-induced acetylation on different plasma
roteins. It increases haemoglobin’s afﬁnity to oxygen and
onsequently reduces the severity of sickle-cell disease [9,10].
cetylation of ﬁbrinogen by ASA improves the porosity of the
brin cloth making it more  accessible to plasmin for the ﬁbri-
olytic process [11]. ASA also acts on low density lipoproteins,
educing their oxidation level and thus exerting a preventive
ffect against atherosclerosis [12]. ASA-mediated acetylation
as also been detected on human serum albumin (HSA) [13].
SA is known to be the most abundant circulating plasma
rotein, and because it has multifunctional properties it plays
ey roles in metabolism. It is the main transporter of drugs,
ormones, fatty acids and other small metabolites. It regu-
ates oncotic pressure, prevents oxidative damage and has
n intrinsic esterase activity. Previous studies showed the
nvolvement of different amino acidic residues in HSA’s reac-
ions with low ASA concentrations (0.1–0.5 mM)  [14,15]. It was
emonstrated that the acetylation of some of these sites had
n impact on HSA’s pseudo-esterase catalytic activity, and
n its afﬁnity for binding to anionic drugs and metabolites
uch as bilirubin and prostaglandins. However, HSA’s beneﬁ-
ial effects are lower in poorly monitored diabetic patients, via
 process termed as ‘aspirin resistance’. This can be attributed
o insufﬁcient doses of ASA, drug interactions, or the genetic
olymorphism of genes involved in thromboxane biosynthe-
is and turnover [16,17]. In addition, because high plasma
lucose levels encourage protein glycation, they might have
 signiﬁcant effect on aspirin resistance and other metabolic
isorders. Glycation is a non-enzymatic post-translational
odiﬁcation, which is boosted under hyperglycaemic con-
itions (blood glucose concentration ≥ 11 mM). It occurs in a
ondensation reaction between the carbonyl group in glucose
or any other reducing sugar, such as fructose and derivatives)
nd a protein’s free amino residues (mostly N-terminal and
ysine). This process leads to the formation of Amadori com-
ounds which then undergo a series of oxidation, dehydration
nd fragmentation reactions, ﬁnally generating advanced gly-
ation end-products (AGE) [18,19]. AGEs are associated to
ong term diabetic complications, such as retinopathy [20,21],
ephropathy [22–24] and macroangiopathy [25,26]; this is due
o the formation of cross-linked structures [27,28] that alter
he structure/function of proteins, their turn-over, and tend
o accumulate in speciﬁc tissues, impairing their homeostasis
29,30].
Apart from its clinical relevance as a more  rapid indi-
ator for glycaemic monitoringl than glycated haemoglobin
HbA1c), glycated HSA has also been described as having
ltered functions in diabetes (glycated albumin levels in
lasma are considered to indicate the glycaemic state over the
ast 3 weeks, while HbA1c indicates the glycaemic state over
he last 3 months) [31–33]. Indeed, it was shown that glyca-
ion signiﬁcantly impairs HSA’s antioxidant properties [34] and
ts drug-binding capacity [35]. Furthermore, the alterations to
SA’s biophysical properties, induced by glycation, increase ( 2 0 1 4 ) 100–113 101
its afﬁnity to the receptor for advanced glycation end-products
(RAGE) [36]. This leads to several cellular dysfunctions, such as:
the intracellular accumulation of lipids in macrophages [37];
the increase of their inﬂammatory activity by inducing NF-B
[38]; the secretion of IL-6 by adipocytes [34]; and the promotion
of neuronal apoptosis in the human brain [39], contributing to
the development of Alzheimer’s-like diseases.
The potential protective role of ASA in inhibiting the gly-
cation mechanism was previously shown in lens crystallins
[40,41], collagen [42], haemoglobin [43] and, most recently,
ﬁbrinogen [44]. However, the impact of increased blood glucose
concentrations and glycation on ASA-mediated acetylation
has been poorly investigated. To date, only Watala et al. have
shown the impairment of ASA-induced protein acetylation on
platelet membrane proteins in diabetes mellitus, due to an
increased level of glycation [45]. Further research is required
to determine how high glucose concentrations might ham-
per the protective action of ASA at the protein level. This
study aimed to highlight HSA’s acetylation response after
incubation, from low to very high ASA concentrations, but
also to elucidate which amino acidic residues showed the
highest reactivity towards ASA. The study’s second aim was
to examine the competition between glycation and acety-
lation in order to demonstrate how these two  reactions take
place at the protein level. Finally, the characterization of the
preferential sites where these two modiﬁcations occur was
performed using mass spectrometry (MS), and the quantiﬁca-
tion of glycated and acetylated peptides of HSA was carried
out using a label-free approach. This proof-of-concept study
lays the foundations for a better understanding of the inter-
action between the ASA-mediated acetylation and glycation
processes on proteins, and gives new insights into their poten-
tial antagonist effects in the pathophysiology of diabetes.
2.  Materials  and  methods
2.1.  Chemicals
Dulbecco’s phosphate-buffered saline (DPBS; 1×, pH 7.4) was
from InvitrogenTM. Human serum albumin (HSA, solution
20%) was obtained from CSL Behring AG. Aspirin (ASA, acetyl-
salicylic acid) was purchased from Aspegic Inject®. Anti
human N-acetyl-lysine monoclonal antibody was from Cell
Signaling Technologies®. ECLTM detection reagent was from
GE Healthcare. Protein assay dye reagent concentrate (liq-
uid) was from Bio-Rad. d-Glucose [12C6] (lyophilized powder,
≥99.5%), Naphtol blue black (lyophilized powder, dye content
ca. 80%), tris-(2-carboxyethyl) phosphine hydrochloride (TCEP;
0.5 M, pH 7.0), iodoacetamide (IAA, crystalline, ≥99%), endo-
proteinase Glu-C from Staphylococcus aureus V8 (lyophilized
powder, 500 U), HPLC-grade water (CHROMASOLV®) and HPLC
grade acetonitrile (ACN; CHROMASOLV®, ≥99.9%) were pur-
chased from Sigma–Aldrich®. Bovine serum albumin (BSA,
lyophilized powder, ≥96%), triethylammonium hydrogen car-solid, 98.0%), magnesium chloride (MgCl2, solid, ≥99.0%),
acetic acid (99.5%), and formic acid (FA; 98.0%) were from
Fluka.
 m i c s102  e u  p a o p e n p r o t e o
2.2.  ASA  and  glucose  incubation  of  HSA
To test the detection limit of ASA-mediated acetylation using
Western blot and LC–MS approaches, ﬁve aliquots of 20 L
HSA were diluted in phosphate buffer up to 200 L, and subse-
quently incubated with several ASA concentrations (20, 2, 0.2,
0.02 and 0 mM)  for 24 h at 37 ◦C. To analyze the impact of high
glucose concentration on ASA’s effects, three aliquots of 20 L
HSA were diluted in phosphate buffer to reach a ﬁnal volume
of 200 L, and then incubated: (1) alone for 24 h at 37 ◦C, (2) with
20 mM ASA for 24 h at 37 ◦C, and (3) sequentially with 10 mM
glucose for 24 h and then 20 mM ASA for 24 h at 37 ◦C. For the
third immunoblot experiment, two groups of three aliquots of
20 L HSA in phosphate buffer (200 L ﬁnal volume) were incu-
bated with 20 mM ASA and different glucose concentrations
(0, 10, and 625 mM)  for 24 h at 37 ◦C; sequential and simulta-
neous incubations were performed for the ﬁrst and the second
group, respectively. Finally, four conditions (200 L ﬁnal vol-
ume) were created: HSA was incubated alone for 24 h at 37 ◦C,
with 20 mM ASA for 24 h at 37 ◦C, with 10 mM glucose for 24 h
at 37 ◦C, and with 10 mM glucose followed by an incubation
with 20 mM ASA for 24 h at 37 ◦C. After incubation, protein
amounts were determined using the Bradford assay, and BSA
was used to create a standard calibration curve.
2.3.  Western  blot  analysis  of  ASA-mediated
acetylation
Samples (200 ng) were separated using electrophoresis on an
8%T/2.6%C polyacrylamide gel and protein transfer was car-
ried out for 1 h at 350 mA.  Membranes were stained with
Amido black [46] to highlight the protein bands, and washed
with water to remove the excess of background. Immunoblot
was carried out with an anti-human antibody against N -
acetyl-lysine in a dilution of 1:5000. The acetylation signal
intensity of the immunoblot was normalized relative to the
corresponding band stained with Amido black. ECL reagents
were used to detect the acetylation signal. Each sample was
evaluated with four experimental replicates (n = 4).
2.4.  Protein  puriﬁcation  and  Glu-C  digestion
After incubation, glucose and salts were removed using Ami-
con Ultra-0.5 mL,  Ultracel® 3K membrane (MilliporeTM) devices
to purify the proteins that were reconstituted in 500 mM TEAB,
pH 8.5. Protein concentrations were subsequently measured
using the Bradford assay, with BSA as the calibration protein.
Samples were split into two experimental groups in order to
analyze the acetylated and glycated peptides separately for
each experimental set. For the acetylation study, 100 g of pro-
tein were diluted in 400 L of TEAB; while for the glycation
study, 1 mg  of protein were diluted in 400 L of TEAB, for sub-
sequent protein digestion. For this purpose, disulﬁde bonds
were reduced using 4 L of TCEP to reach a ﬁnal concentra-
tion of 5 mM and the reaction mixture was incubated for 1 h
at 60 ◦C. Cysteine groups were alkylated using 10 L of IAA to
reach a ﬁnal concentration of 20 mM,  and incubation was car-
ried out for 30 min  at room temperature in dark conditions.
Freshly prepared endoproteinase Glu-C (1 mg/mL) was added
in a ratio of 1:10 (w/w), and digestion took place for 16 h at 3 ( 2 0 1 4 ) 100–113
37 ◦C. For acetylation analysis, digestion mixtures were evap-
orated under speed vacuum, and directly reconstituted in 5%
ACN/0.1% FA for the subsequent desalting procedure. For the
glycation analysis, peptide digests were evaporated and recon-
stituted in mobile phase A (200 mM NH4Ac, 50 mM MgCl2, pH
8.1) to reach an estimated concentration of 16 mg/mL, for the
fractionation of glycated peptides.
2.5.  Enrichment  of  glycated  peptides  by  boronate
afﬁnity  chromatography
Reconstituted peptides were enriched using boronate afﬁn-
ity chromatography—by interaction between cis-diol groups of
glycated peptides, present at low concentration, and boronate
groups of the stationary phase, as previously described [47,48].
For this purpose, a 50 L room temperature sample was
injected in a Waters 600E HPLC system equipped with a TSK-
Gel boronate afﬁnity column from Tosoh Bioscience (7.5 cm
length × 7.5 mm inner diameter, i.d., 10 m particle size). A
chromatographic method based on a gradient with two iso-
cratic steps was used to separate non-glycated from glycated
fractions. Step 1 was a 0–10 min, 100% mobile phase A (200 mM
ammonium acetate, 50 mM magnesium chloride, pH 8.1) for
retention of glycated peptides by esteriﬁcation of the 1,2
cis-diol group of glucose moieties and the hydroxyl groups
of boronate ligands under alkaline conditions. Non-glycated
peptides were eluted. Step 2 was a 10–20 min, 100% mobile
phase B (100 mM acetic acid) for the elution of glycated pep-
tides under acidic conditions; 20–30 min, 100% mobile phase A
to bring the column back to the initial equilibrium conditions.
The glycated fraction was collected for subsequent evapora-
tion and reconstitution in 5% ACN/0.1% FA, for the ensuing
desalting and concentration.
2.6.  LC–MS/MS  detection  of  acetylated  and  glycated
peptides
Samples from acetylated and glycated data sets were desalted
and pre-concentrated using a MacroSpin ColumnTM C18 (Har-
vard Apparatus), according to the manufacturer’s protocol.
Peptides were eluted in 400 L of 50% ACN/0.1% FA and then
evaporated to dryness before reconstitution in 5% ACN/0.1%
FA, prior to LC–MS/MS analysis. Peptide digests were analyzed
using electrospray ionization in positive ion mode (1.6 kV ion-
ization voltage), on an Orbitrap hybrid linear ion trap (Thermo
Fisher). Nanoﬂow was carried out using a Waters NanoAquity
HPLC system consisting of a pre-column (100 m inner diame-
ter and 18 mm in length) packed with C18 resin, where peptides
are initially loaded and trapped at a ﬂow rate of 3 L/min in
water/ACN (95/5, v/v) with 0.1% FA. After retention, peptides
were eluted using an ACN gradient developed in an analytical
column packed with C18 resin, at the ﬂow rate of 200 nL/min
with mobile phase A (water, 0.1% FA) and B (ACN, 0.1% FA). The
mass spectrometer was operated in data-dependent MS/MS
mode with a precursor-ion scan range of 400–1600 m/z  and
a resolving power of 60,000. Each sample in both data sets
was analyzed four times using high energy collisional dissoci-
ation (HCD) as the activation mode. The 3 most abundant ions
detected from the MS  survey scan were selected as precur-
sor ions for fragmentation (normalized collision energy, 40%),
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ollowed by Orbitrap detection with a resolving power of 7500
ith a dynamic exclusion of 45 s, to minimize repeated anal-
sis of the same precursor ion. All analyses were carried out
sing four replicate injections.
.7.  Data  analysis
fter data-dependent acquisition, peak lists were generated
rom raw data using EasyProtConv v1.5 software, and the
esulting data ﬁles were searched for matches against the
niProtKB/Swiss-Prot database (Release June 13, 2012, 647,369
ntries) using the EasyProt v2.2 (build 612) tool [49]. Because
his study analyzed human albumin, we selected Homo sapi-
ns taxonomy for the protein search. The high resolution of the
cquired data allowed the scoring model to use an accuracy
f 6 ppm on fragments and 10 ppm on precursors. Common
mino acid modiﬁcations detected were carbamidomethyla-
ion of cysteine residues (57.0215 Da) and oxidized methionine
15.9949 Da); these were set as ﬁxed and variable modiﬁ-
ations, respectively. Additional variable modiﬁcations, for
cetylation and glycation, were selected on lysine residues
nd N-terminal positions. For the analysis of acetylated
eptides, the selection of acetylation-induced modiﬁcation
as based on the peptide attachments of the acetyl group
42.0100 Da), while for the selection of glycated peptides, the
ass shift was built on the attachment of the entire glucose
olecule (162.0523 Da). The number of modiﬁcations per pep-
ide was set to a maximum of 2 in order to reduce the search
pace of all possible combinations of variable modiﬁcations.
ndoproteinase Glu-C was selected as the cleavage enzyme,
ith three potential missed cleavages allowed. The minimum
eptide length was 8, with a minimum peptide z-score of 4.
our analytical injections per sample, each analyzed in inde-
endently, provided replicate data values. The peak list ﬁles
btained for each technical replicate were merged and sub-
itted for the database search. For the signiﬁcance of peptide
dentiﬁcation we  used a false-discovery rate of 5%. Peptides
ere considered as identiﬁed if they were present 2 times out
f 4, but the majority of them were found at least 3 times out
f 4.
.8.  Peptide  quantiﬁcation
abel-free quantitation of glycated and acetylated peptides
rom HSA was done using Nonlinear Dynamics’ Progenesis
oftware. This relies on the accurate alignment of m/z and
t features for every chromatographic run in each group. A
lobal peak list ﬁle, containing all the features detected, was
sed to query the database as above and, from the identiﬁ-
ation results, a pepXML ﬁle was exported to Progenesis. All
he identiﬁed peptides were then matched using their rela-
ive features. Quantitation is carried out using the normalized
bundance for each peak corresponding to features and com-
aring it to the same peak for all the conditions analyzed. The
ormalization of peptide abundance was performed automat-
cally by Progenesis. Brieﬂy, the software selects one technical
eplicate as a reference; after calculating the raw intensities for
ach peptide on each replicate, it determines the ratio between
he replicate being normalized and the reference replicate.
hen, a distribution of log (ratios) is calculated and a global ( 2 0 1 4 ) 100–113 103
scaling factor (the anti-log of the average of the log (ratios))
is determined. The raw intensities for each peptide among
different replicates are multiplied by the global scaling factor.
3.  Results  and  discussion
For several decades, ASA and ASA derivatives have been
shown to have a signiﬁcant biological and clinical effects.
One of these effects relies on ASA’s protective action against
protein glycation, and has been clearly documented using
in vivo and in vitro models [50,51]. Indeed, modiﬁcations in
both environments occur at the same functional groups on
proteins, but it is not clear whether acetylation and gly-
cation share the same target sites, and are thus in direct
competition, or whether they target different sites and thus
induce potential conformational changes in protein struc-
tures. This study’s purpose was to characterize the effects of
glucose on ASA-mediated acetylation using an in vitro model
based on HSA. Only one previous study demonstrated an
association between glycation and ASA on HSA [50], but it
reported no particular information regarding the exact sites
at which these modiﬁcations were involved. The current
study established a relationship between ASA-induced acet-
ylation and protein glycation, starting from the analysis of
the preferential acetylated sites on HSA and moving on to the
inﬂuence that high glucose concentration might have on the
acetylation process, and vice versa, through label-free quantiﬁ-
cation.
3.1.  Qualitative  and  quantitative  analysis  of
acetylation  and  glycation  on  HSA
The present study used a proteomic workﬂow for the analy-
sis of acetylation and glycation on HSA; this comprised both
immunoblot and tandem mass spectrometry (MS) approaches.
These gave qualitative and quantitative estimations of the
extent of these two modiﬁcations at the protein level (Fig. 1).
Following exposure to ASA, and after glucose and ASA co-
incubation, the acetylation level of native HSA was ﬁrst
measured by a Western blot test using an anti-acetyl lysine
antibody, as previously mentioned. The immunoreaction
signal was normalized on the corresponding Amido-black
stained band on the same blot. Intensity values were mea-
sured using TotalLab Quant software. For the MS  analysis,
a new condition was created in which HSA was incubated
with glucose alone, in addition to the other 3 used for
immunoblot. Samples were puriﬁed from glucose and ASA,
and then digested with endoproteinase Glu-C. The choice of
this enzyme is supported by the fact that acetyl groups and
glucose attachments are selective for lysine residues, and for
this reason the trypsin digestion pattern can be affected by
an increase of missed cleavage sites. The inﬂuence of these
two modiﬁcations is less dramatic for endoproteinase Glu-
C, and the identiﬁcation of missed cleavage sites might be
considerably reduced. After digestion, two distinct data sets
were created: one for acetylated peptide analysis and one for
glycated peptide analysis.
Concerning mass spectrometry, electron transfer dissoci-
ation (ETD) [52] and collision induced dissociation (CID) in
104  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 100–113
Fig. 1 – Proteomic workﬂow for the characterization of acetylation and glycation on HSA. The schema shows the different
phases of the analysis from sample preparation to the data processing for the identiﬁcation and quantiﬁcation of acetylated
and glycated peptides.
neutral loss scanning and multistage activation [53] with an
ion trap mass analyzer have successfully proved their efﬁ-
ciency in data-dependent methods for the identiﬁcation of
glycated peptides. Nevertheless, coupling HCD fragmenta-
tion with Orbitrap detection also allowed the obtainment
of high quality MS/MS  spectra, which enhanced the identi-
ﬁcation of acetylated and glycated peptides. HCD employs
higher dissociation energies by using nitrogen as the colli-
sion gas; this results in more  efﬁcient fragmentation than
with the helium-based dissociation occurring in CID. More-
over, HCD activation mode is faster than with CID, leading to
high vibrational energies before dissociation of the molecular
ion. This is fundamental for the analysis of modiﬁed pep-
tides in which functional groups are retained on the peptide
backbone during the fragmentation process [54]. The present
study used HCD fragmentation, and two data ﬁles were cre-
ated for the subsequent identiﬁcation and quantiﬁcation bylabel-free quantiﬁcation of acetylated and glycated peptides,
with localization of the target sites where these two modiﬁca-
tions occurs.
3.2.  Analysis  of  the  detection  limit  of  ASA-mediated
acetylation  on  HSA
Acetylation levels of HSA exposed to decreasing concentra-
tions of ASA were analyzed. Immunoblot analysis clearly
revealed a strong acetylation reaction when HSA was
incubated with 20 mM ASA; this decreased considerably
(−85%) with 2 mM ASA incubation. No immunoreactivity
was detected after 0.2 and 0.02 mM ASA exposure (Fig. 2),
conﬁrming the inability of this analytical technique to detect
low acetylation levels on proteins. On the other hand, the high
sensitivity of MS analysis allowed the obtainment of more
informative results. The degree of acetylation was directly
e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 100–113 105
Fig. 2 – Acetylation of HSA as a function of ASA
concentration. (A) A scalar concentration of 20, 2, 0.2 and
0.02 mM of ASA was used to assess the detection limit of
acetylation on immunoblot. (B) Amido black staining. (C)
Bar plot of the normalized intensities among N = 4
r
p
0
o
b
t
Fig. 4 – Impact of high glucose concentration on ASA
acetylation. Western blot analysis of HSA (lane 1),
HSA + 20 mM ASA (lane 2), HSA + 10 mM glucose + 20 mM
ASA (lane 3). (A) Immunoblot with an anti-acetyl lysine
speciﬁc Ab. (B) Amido black staining. (C) Bar plot of the
F
teplicates.
roportional to the ASA concentration used (from 20 to
.02 mM);  Fig. 3A and B shows the decrease in the total number
f unique acetylated peptides and sites, respectively. It should
e noted that the higher number of acetylated sites, compared
o the number of acetylated peptides can be explained by the
ig. 3 – Analysis of the acetylation detection limit with LC–MS/M
he total number of unique acetylated peptides, and (B) unique anormalized intensities of N = 4 replicates.
low digestive efﬁciency of Glu-C; because it produces longer
peptides than those generated by trypsin digestion,
this increases the number of sites modiﬁed per pep-
tide sequence. However, when HSA was incubated with
0.02 mM ASA, the reverse situation was found, with a
total of 7 acetylated peptides and 6 acetylated sites.
This can be explained by the presence of two unique
peptides, which modify the same Lys residue, but that
differ in the presence of one missed cleavage site. The
detailed list of acetylated peptides and their corresponding
identiﬁed sites are shown in Table 1. MS analysis enabled the
S. Correlation between the concentration of ASA, and (A)
cetylated sites.
106  e u  p a o p e n p r o t e o m i c s 3 ( 2 0 1 4 ) 100–113
Table 1 – Acetylated peptides and sites identiﬁed at decreasing ASA concentration. The precise site of modiﬁcation is
shown for each condition.
Peptide Position HSA + 20 mM
ASA
HSA + 2 mM
ASA
HSA + 200 M
ASA
HSA + 20 M
ASA
HSA
AKRMPCAEDYLSV- VLNQLCVLHE 443–465 444
CCHGDLLECADDRAD-
LAKYICENQDSISSKLKE
245–277 257
FAKTCVADESAENCDKS-
LHTLFGDKLCTVATLRE
49–82 51,64,73 51,64 51,64
FAKTCVADESAENCDKSLH-
TLFGDKLCTVATLRETYGE
49–86 51,64 51,64 51,64
GKKLVAASQAALGL 572–585 573,574 573,574
GKASSAKQRLKCASL- QKFGE 189–208 197
KCCAAADPHECYAKVFDE 359–376 359
KTPVSDRVTKCCTE 466–479 466,472,475
KCCKADDKETCFAEE 557–571 557,564 557,564 560,564
KERQIKKQTALVE 519–531 521,525
LLFFAKRYKAAFTE 154–167 159
LRDEGKASSAKQRLKC- ASLQKFGE 185–208 186,190,195,197,199 186,195,199 199
LVKHKPKATKEQLKAV-
MDDFAAFVE
532–556 536 545
MADCCAKQEPERNECFLQH-
KDDNPNLPRLVRPE
87–119 93 93 93
NCDKSLHTLFGDKLCTVATLRET-
YGEMADCCAKQEPERNE
61–100 81 81
NQDSISSKLKE 267–277 274,276 276
QLKAVMDDFAAFVEKCCKADDKE 543–565 545 545
RQIKKQTALVE 521–531 524,525 524,525 524,525
SLVNRRPCFSALEVDETYV-
PKEFNAE
480–505 500
TFTFHADICTLSEKE 506–520 519 519 519
TYGEMADCCAKQEPERNE 83–100 93 93 93 93 93
TYGEMADCCAKQEPERNECFL-
QHKDDNPNLPRLVRPE
83–119 93 93 93 93
VAHRFKDLGEE 7–17 12
VSRNLGKVGSKCCKHPE 426–442 432,439 432,439
VTEFAKTCVADESAENCDKSLH-
TLFGDKLCTVATLRE
46–82 51YARRHPDYSVVLLLRLAKTYE 334–354 351
characterization of acetylation even when HSA was exposed to
low doses of ASA (0.2 and 0.02 mM),  levels at which detection
using immunoblot was impossible. Indeed, identifying sites
that showed a high tendency to be acetylated by ASA was an
important aspect of analysis. HSA’s reaction with 0.02 mM ASA
yielded 6 modiﬁed sites: Lys 51, 64, 93, 444, 545 and Arg 81.
This is the ﬁrst time that the identity of these sites has been
reported at such a low ASA concentration. Furthermore, this
method revealed native acetylation, which allowed the iden-
tiﬁcation of Lys 93 residue. The high tendency of these sites
to be acetylated by ASA might be attributable to their location
at the protein surface, or to the surrounding basic residues
that impede their protonation. With 0.2 mM ASA, the number
of modiﬁed sites increased and it was possible to detect the
two known preferential acetylation sites in Lys 199 and 519,
as previously reported [15,55]. Differently from Lys 519, which
is an external site, Lys 199 is present in an internal pocket of
the protein, and owes its high reactivity to the low pKa of its
side chain. A further increase of acetylated residues was found
after incubation with 2 mM and 20 mM ASA, but this would be
less likely to occur in vivo since these two concentrations are
much higher than ASA’s therapeutic range (0.1–0.5 mM)  [14].3.3.  Glycation  effects  on  HSA’s  ASA-mediated
acetylation
This study investigated the inﬂuence of glycation on HSA’s
acetylation as induced by ASA. The degree of acetylation of
native HSA was compared with those of HSA after 24 h ASA
incubation, both with and without exposure to glucose. The
immunoblot showed a visible difference in the reactions under
the different conditions tested. The acetylation signal in HSA
incubated with ASA alone (Fig. 4, lane 2) was clearly lower
than the signal in HSA incubated with ASA and glucose (Fig. 4,
lane 3), and no signal was detected in native HSA (Fig. 4, lane
1). These results convincingly showed that glycation signiﬁ-
cantly affects protein acetylation when HSA is incubated with
10 mM of glucose and 20 mM ASA; this suggested that high
glucose concentrations had a direct impact, even when the
ASA concentration was far beyond the normal therapeutic
level in blood. Indeed, the concentration of ASA used in this
study was higher than the therapeutic plasma range precisely
to enhance the acetylation process and to reach a quasi-
saturated state of albumin. Because the physiological plasma
levels of ASA are around 0.2–1.5 mM,  we assumed that by using
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Fig. 5 – Extracted ion chromatograms in MS2  of immonium ions calculated for (A) acetylated, and (B) glycated Lys in HSA
after 20 mM  ASA and 10 mM glucose incubation, respectively. Tandem mass spectra highlighting the presence of (C)
a s.
a
o
t
tcetylated immonium ions, and (D) glycated immonium ion
n ASA concentration 20 times higher, the level of occupancy
f the lysine sites would be near to completeness; any varia-
ion of the degree of acetylation, therefore, would be due to
he glucose effect. Moreover, another of the study’s aims was
Table 2 – Acetylated peptides and sites identiﬁed. The precise s
Peptide Position 
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRE 49–82 
GKASSAKQRLKCASLQKFGE 189–208 
GKKLVAASQAALGL 572–585 
KCCAAADPHECYAKVFDE 359–376 
KERQIKKQTALVE 519–531 
KCCKADDKETCFAEE 557–571 
LLFFAKRYKAAFTE 154–167 
LRDEGKASSAKQRLKCASLQKFGE 185–208 
LVKHKPKATKEQLKAVMDDFAAFVE 532–556 
MADCCAKQEPERNECFLQHKDDNPNLPRLVRPE 87–119 
NQDSISSKLKE 267–277 
RQIKKQTALVE 521–531 
SLVNRRPCFSALEVDETYVPKEFNAE 480–505 
TFTFHADICTLSEKE 506–520 
TFTFHADICTLSEKERQIKKQTALVE 506–531 
TYGEMADCCAKQEPERNE 83–100 
TYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPE 83–119 
VSRNLGKVGSKCCKHPE 426–442 
YARRHPDYSVVLLLRLAKTYE 334–354 to characterize the higher number of preferential acetylation
sites on HSA.
The degree to which acetylation is inhibited is depend-
ent on the extent of glycation. Indeed, as the glucose
ite of modiﬁcation is shwon for each condition.
HSA HSA+20 mM
ASA
HSA+10 mM
glucose
HSA+20 mM
ASA+10 mM
glucose
51,64,73 51,64,73
190
573,574 573,574
359
519,521,525 521,525
557,564 557,560
159
186,190,195,199 199
536,545 536,545
93
274,276
524,525
500
519 519
519 519
93 93 93 93
93 93
432,439
351 351
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Table 3 – Glycated peptides and sites identiﬁed. The precise site of modiﬁcation is shown for each condition.
Peptide Position HSA HSA + 20 mM
ASA
HSA + 10 mM
glucose
HSA + 20 mM
ASA + 10 mM
glucose
CADDRADLAKYICE 253–266 262 262 262 262
CCHGDLLECADDRADLAKYICE 245–266 257,262 257,262 257,262
CCQAADKAACLLPKLDE 168–184 174 174
CFLQHKDDNPNLPRLVRPE 101–119 106 106
FAEVSKLVTDLTKVHTE 228–244 233 233 233,240
FAKTCVADESAENCDKSLHTLFGDKLCTVATLRE 49–82 64 64 51,64 51,64
FKPLVEEPQNLIKQNCE 377–393 378 378
GKASSAKQRLKCASLQKFGE 189–208 195 197
GKKLVAASQAALGL 572–585 574 574 574
KCCAAADPHECYAKVFDE 359–376 372 372 372 372
KCCKADDKETCFAEE 557–571 564 564
KERQIKKQTALVE 519–531 525 525 525
KTPVSDRVTKCCTE 466–479 472,475 475 466,472,475
LRDEGKASSAKQRLKCASLQKFGE 185–208 197,199 195,197,199 195,197,199 195,197,199,205
LVKHKPKATKE 532–542 536 534
MADCCAKQEPERNE 87–100 93 93 93
NCDKSLHTLFGDKLCTVATLRE 61–82 64,73 64,73 64,73 64,73
NQDSISSKLKECCEKPLLE 267–285 274
RAFKAWAVARLSQRFPKAE 209–227 209,218
RNECFLQHKDDNPNLPRLVRPE 98–119 106
RQIKKQTALVE 521–531 524,525 525 524,525 525
SAENCDKSLHTLFGDKLCTVATLRE 58–82 64,73 64,73 64,73 64,73
SLVNRRPCFSALEVDETYVPKEFNAE 480–505 500
TFTFHADICTLSEKE 506–520 519 519 519
TTLEKCCAAADPHECYAKVFDE 355–376 372
93 
233 
436 TYGEMADCCAKQEPERNE 83–100 
VSKLVTDLTKVHTE 231–244 
VSRNLGKVGSKCCKHPE 426–442 
concentration increased, a signiﬁcant decrease of the acet-
ylation immunoreaction signal was detected across the
different conditions tested (Supplementary data Fig. S1). The
level of acetylation was signiﬁcantly lower after incubation
with 625 mM glucose, showing that inhibition of the ASA reac-
tion is directly correlated to the glucose concentration.
3.4.  Detection  of  modiﬁed  immonium  ions  to  conﬁrm
the presence  of  modiﬁed  peptides
The high fragmentation efﬁciency of HCD, coupled with its
high resolution, high accuracy and the no low mass cut-off of
Orbitrap detection, revealed the presence of immonium ions
that were clearly visualized in the low mass range, conﬁrming
peptide identiﬁcation. These immonium ions made it possi-
ble to pinpoint the presence of modiﬁed amino acids, such as
acetylated and glycated lysine residues. The most frequent Lys
immonium ion provided a signal at 84.081 Da, which shifted
to 126.091 Da after acetyl group attachment and to 246.134 Da
after glucose attachment. However, in the latter case, the typ-
ical neutral losses detected in glycated peptides should be
taken into account, such as the loss of three water molecules
(−54.031 Da), and the intramolecular rearrangement of the
glucose moiety (−84.042 Da), which generated signals at
192.102 and 162.091 Da, respectively. Because of the selectivity
of these ions, acetylated and glycated peptides can be local-
ized by extracting ion chromatograms in MS/MS (Fig. 5A and
B). These were monitored at 126.09 m/z for the acetyl-lysine
immonium ion (Fig. 5C) and at 162.09 and 192.10 m/z for the
furylium- and pyrylium-lysine immonium ions, respectively93 93 93
233 233 233
432,436,439 432,436,439 432,436
(Fig. 5D). These ﬁngerprints provided additional evidence for
the assignment of acetylated and glycated peptides, respec-
tively [47]. Due to the high accuracy of the instrument used,
it was possible to precisely select the m/z of either the lysine
acetylated or glycated immonium ion which deﬁned the pres-
ence of a modiﬁed residue in the MS/MS spectrum.
3.5.  Quantitation  of  acetylated  and  glycated  peptides
on HSA
The application of this protocol provided proﬁles of the acety-
lated and glycated peptides including their modiﬁcation sites
on HSA. From a qualitative point of view, the total number
of unique acetylated peptides was considered for each condi-
tion. Only one unique acetylated peptide was found in native
HSA and in HSA after glucose exposure. However, this number
increased to 12 peptides after simultaneous incubation with
glucose and ASA, and up to 18 after ASA incubation alone
(Table 2). It was observed that most of the sequences of acety-
lated peptides contained at least two modiﬁed sites; this was
ascribed to the low efﬁciency of Glu-C, as mentioned above.
On the glycation side, 17, 21, 22 and 18 unique glycated pep-
tides were found in native HSA, HSA after incubation with
20 mM ASA, HSA after incubation with 10 mM glucose, and
HSA after simultaneous glucose and ASA incubation, respec-
tively (Table 3). The level of glycation and acetylation on HSA
was measured using label-free quantitation. This method is
based on the precise alignment of chromatographic peaks
derived from the Rt and m/z features of each peptide identi-
ﬁed. Raw LC–MS data were imported into Nonlinear Dynamics’
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Fig. 6 – Quantiﬁcation of glycation and acetylation on HSA. (A) Abundance distribution for all glycated peptides for each
condition. (B) Peak abundance for a representative glycated peptide. (C) Abundance distribution for all acetylated peptides
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dor both conditions. (D) Peak abundance for a representative
rogenesis analysis software where the feature extraction
nd alignment processes take place across all the replicates
or each condition. As previously explained, the identiﬁca-
ion results derived from all the peak lists were associated
o their respective features and the peak totals for each pep-
ide was calculated. Using this approach, 18, 18, 21 and 20
nique glycated peptides were quantiﬁed for native HSA, HSA
fter incubation with 20 mM ASA, HSA after incubation with
0 mM glucose, and HSA after simultaneous incubation of
0 mM glucose and 20 mM ASA, respectively. Taking all the gly-
ated peptide totals measured in each condition, a signiﬁcant
ecrease was observed between when ASA and glucose are
ncubated together and when glucose was incubated alone
Fig. 6A). Across all 4 conditions, 11 glycated peptides were
ound to be in common in all 4 conditions and all of them
howed a signiﬁcant decrease in glycation levels when ASA
as incubated with glucose. Fig. 6B shows data from a rep-
esentative glycated peptide (TFTFHADICTLSEKE) of HSA in
rder to highlight ASA’s protective effects against glycation.
ig. 6C represents the total abundance of the acetylated pep-
ides. No acetylated peptides were quantiﬁed for either native
SA or HSA with 10 mM glucose. However, the peak abun-
ance of 12 and 9 unique acetylated peptides was measuredylated peptide. *p ≤ 0.05, **p ≤ 0.01, ***p  ≤ 0.005.
for HSA after 20 mM ASA incubation and after glucose and ASA
co-incubation, respectively. This lends further evidence to the
theory of mutual competition between these two  uncontrolled
post-translational modiﬁcations. Across both conditions in
which the acetylation level was measured, only 5 quantiﬁed
peptides were found in common. Fig. 6D shows HSA’s TFTFHA-
DICTLSEKE peptide (also found to be glycated) which better
illustrates the blocking effect of glucose on ASA-mediated
acetylation at the protein level. Taking into account the num-
ber of modiﬁed peptides (from the acetylation and glycation
data sets), and the unmodiﬁed form of the same peptides, the
extents of acetylation and glycation in HSA were calculated
at 42% and 13%, respectively. Taken together these results
demonstrate a relevant interaction between these two mod-
iﬁcations: from one side ASA tends to reduce the glycation
level through the acetylation of preferential sites, and on the
other, glucose hampers the ASA effect by decreasing the acet-
ylation content of the protein, as also conﬁrmed by Western
blot. These results represent the ﬁrst proof of the interplay
between ASA and glucose at the protein level, suggesting a
potential competition effect induced by glucose reducing the
content of acetylation, and on the other side, induced by ASA,
protecting the protein from further glycation.
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Fig. 7 – Analysis of glycated and acetylated sites on HSA. (A) Venn diagram between glycated and acetylated sites on HSA
after glucose and aspirin incubation. (B) Solvent accessibility surface area of the crystal structure of HSA (pdb: 1UOR) with
the 8 common modiﬁed lysine residues.
3.6.  Localization  of  glycation  and  acetylation  sites  on
HSA
The precise sites of glycation and acetylation modiﬁcations
on HSA were analyzed in order to characterize the potential
amino acid targets. A unique acetylated site (Lys 93) was found
both in native HSA and HSA after glucose incubation; while
HSA after ASA incubation identiﬁed 26 unique acetylated sites,
and HSA incubated with glucose and ASA identiﬁed 15 unique
acetylated sites (Table 2). Lys 199 and Lys 519 were found to be
common to both types of incubations and had been reported
as preferential acetylation sites in a recent study [15].Glycation analysis yielded 15 unique glycated sites endoge-
nous in native HSA, of which Lys 525 had been previously
reported as a highly reactive glycation site [56,57]. In addition,
glycation on native HSA was also detected at Lys 64, 73, 93,
199, 233, 262, 372, 436, 475, 519 and 524. Most of these residues
were located at the protein surface exposed to the solvent or
close to basic amino acids in the tertiary structure, thus mak-
ing them more  likely to the attach to glucose. The number of
glycated sites increased to 27 after glucose incubation and to
21 when glucose and ASA were co-incubated (Table 2). Most
of the sites identiﬁed were consistent with those reported by
previous works in which high glycation levels were analyzed
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19,37]. To assess which sites were shared by acetylation and
lycation modiﬁcations, the data sets of acetylated and gly-
ated sites obtained from the sequential incubation of glucose
nd ASA were compared. Eight sites (Lys 51, 64, 73, 93, 199, 519,
25 and 574) were found to be in common (Fig. 7A). Of these,
ys 93 was detected as a native HSA acetylated and glycated
ite, Lys 525 was previously shown to be a major glycation site,
nd residues Lys 199 and 519 were found to be highly respon-
ive to ASA. Fig. 7B shows the crystal structure of HSA, with
ts solvent accessible surface area, and the 8 modiﬁed lysines
re represented by coloured sticks (Fig. 7B). With the exception
f Lys 199, which is present in an internal pocket, the spatial
istribution of the other sites’ modiﬁed residues shows them
o be on surfaces of the protein, readily accessible to the sol-
ent, thus explaining their high tendency to acetylation and
lycation. Surface solvent accessibility is deﬁned as the sur-
ace traced by the centre of an ideal sphere with a radius of
.4 A˚ as it rolls across the protein’s van der Walls surface, and it
s calculated using the rolling ball algorithm present in PyMOL
1.6 software.
Looking at the MS/MS  spectrum for each of these sites, it
as possible to highlight the peptide backbone, with identi-
cation of its y and b ions, together with the relative mass
isplacements due to the modiﬁcations. As an example, Fig.
2A and B in the Supplementary data shows the MS/MS
pectrum for the acetylated and glycated forms of HSA’s
FTFHADICTLSEKE peptide at Lys 519. The elucidation of new
olecular targets for both ASA-induced acetylation and gly-
ation could have important consequences on the biological
unctions of HSA. The presence of residues modiﬁed by an
cetyl group or a glucose attachment could induce conforma-
ional changes of different protein regions, thus inﬂuencing
SA’s afﬁnity for binding to metabolites, drugs and fatty acids.
ndeed, most of these interactions occur in pockets on the
rotein’s surface, which is where this study identiﬁed the
ajority of acetylated and glycated sites. Furthermore, many
ther molecular processes could be affected by this interplay
etween acetylation and glycation, such as HSA’s aforemen-
ioned antioxidant activity or its pseudo-esterase activity.
nterestingly, one of the residues this study found to be acety-
ated (Arg 472) is very close to Tyr 411 (11.67 A˚) (data not
hown), HSA’s central site of the esterase activity [58]; it is also
lose to Lys 199, which was seen to be both acetylated and
lycated. Thus, depending on the extent to which these two
on-enzymatic, post-translational modiﬁcations occur, and
heir competition for the same chemical groups, their roles
n protein structures and functions could be different, leading
o signiﬁcantly altered protein responses.
.  Conclusion
he present work aimed to evaluate the extent of HSA acet-
lation using a range of ASA doses, and to demonstrate the
nﬂuence of glycation on the acetylation process. A dose-
ependent increase in the number of acetylated peptides and
ites was observed after in vitro incubation with ASA. The
igniﬁcant impact that high glucose levels have on limiting
rotein acetylation was also demonstrated, and the favoured
cetylation and glycation sites on HSA were characterized. ( 2 0 1 4 ) 100–113 111
Finally, a label-free quantitation was performed to better con-
ﬁrm the interplay and the reciprocal competition between
glycation and ASA acetylation. Our pilot study has laid down
the foundations for a more  extensive future qualitative and
quantitative analysis of acetylated and glycated proteins in
clinical blood samples. This will help better evaluate whether
these phenomena occur in vivo and to deﬁne their relevance
to the pathophysiological mechanisms related to diabetes.
Appendix  A.  Supplementary  data
Supplementary material related to this article can be found,
in the online version, at doi:10.1016/j.euprot.2014.02.001.
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